Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine

Journal of Infectious Diseases

Volumn 201, Issue 8, 2010, Pages 1183-1191

  Cohen, Jeffrey I ^a   Hohman, Patricia ^a   Fulton, Rachael ^a   Turk, Siu Ping ^a   Qin, Jing ^b   Thatcher, Karen ^c   Hornung, Ronald L ^c  

^a Laboratory of Clinical Infectious Diseases   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; SMALLPOX VACCINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; HEADACHE; HUMAN; KINETICS; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; RECIPIENT; VACCINATION;

ADULT; CHEMOKINE CXCL10; CYTOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; INTERFERONS; INTERLEUKINS; KINETICS; MALE; MIDDLE AGED; MONOKINES; RECEPTORS, TUMOR NECROSIS FACTOR; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77950255720     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651453     Document Type: Article

References (33)

1. Fenner F, Henderson DA, Arita I, Jerek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988.
2. Frey S, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-1274
3. Talbot TR, Stapleton JT, Brady RC, et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004;292:1205-1212
4. Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003;289:3295-3299
5. Greenberg RN, Kennedy JS, Clanton, DJ, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calflymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005;365:398-409.
6. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. J Infect Dis 2004;189:1401-1410
7. McKinney BA, Reif DM, Rock MT, et al. Cytokine expression patterns associated with systemic adverse events following smallpox immunization. J Infect Dis 2006;194:444-453
8. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159:119-135
9. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K. Gamma interferon (IFN-y) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-7 ligand null-mutant mice. J Virol 1999;73:5196-5200
10. Liu G, Zhai Q, Schaffner DJ, Wu A, Yohannes A, Robinson TM, et al. Prevention of lethal respiratory vaccinia infections in mice with interferon-α and interferon-γ. FEMS Immunol Med Microbiol 2004;40: 201-206
11. Kohoncn-Corish MR, King NJ, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia vims expressing interferon-gamma. Eur J Immunol 1990;20:157-161
12. Mahalingam S, Farber JM, Karupiah G. The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo. J Virol 1999;73:1479-1491
13. Alcamí A, Smith GL. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995;69:4633-4639
14. Symons JA, Tscharke DC, Price N, Smith GL. A study of the vaccinia virus interferon-y receptor and its contribution to virus virulence. J Gen Virol 2002;83:1953-1964
15. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity. J Virol 2001;75:11-18
16. Sakala IG, Chaudhri G, Butter RM, et al. Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection. J Virol 2007;81:3346-3353
17. Arsenio J, Deschambault Y, Cao J. Antagonizing activity of vaccinia virus E3L against human interferons in Huh7 cells. Virology 2008;377: 124-132.
18. Reading PC, Smith GL. Vaccinia virus intcrlcukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 2003;77:9960-9968
19. Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Statl activation. J Virol 2001;75:3185-3196
20. Thijs LG, Hack CE. Time course of cytokine levels in sepsis. Intensive Care Med 1995;21:S258-63.
21. Lidbury BA, Aston R, Ramshaw IA, Cowden WB, Rathjen DA. The enhancement of human tumor necrosis factor-alpha antiviral activity in vivo by monoclonal and specific polyclonal antibodies. Lymphokine Cytokine Res 1993;12:69-74.
22. Sambhi SK, Kohonen-Corish MR, Ramshaw IA. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci USA 1991;88:4025-4029
23. Ruby J, Bluethmann H, Peschon JJ. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 1997;186:1591-1596
24. Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J. Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kB, and IRF3 pathways. J Virol 2009;83:6757-6768
25. Reading PC, Khanna A, Smith GL. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 2002;292:285-298
26. Alcamí A, Khanna A, Paul NL, Smith GL. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol 1999;80:949-959
27. Kettle S, Alcamí A, Khanna A, Ehret R, Jassoy C, Smith GL. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-lß-converting enzyme and protects virus-infected cells from. TNF- and Fas-mediated apoptosis, but does not prevent IL-1ß-induced fever. J Gen Virol 1997; 78:677-685
28. Kopf M, Baumann H, Freer G, et al. Impaired immune and acutephase responses in interleukin-6-deficient mice. Nature 1994;368: 339-342
29. Ramsay AJ, Husband AJ, Ramshaw IA, et al. The role of interleukin6 in mucosal IgA antibody responses in vivo. Science 1994;264:561-563
30. Alcamí A, Symons JA, Collins PD, Williams TJ, Smith GL. Blockade of chemokinc activity by a soluble chemokinc binding protein from vaccinia virus. J Immunol 1998;160:624-633
31. Murphy J, Wright R, Bruce GK, et al. Eosinophilic-lymphocytic myocarditis after smallpox vaccination, Lancet 2003;362:1378-1380
32. Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005;294:2734-2743
33. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-1208